Stock Market & Financial Investment News

News Breaks November 11, 2012 20:02 EDT MRK Merck announces interim results evaluating MK-5172 in HCV therapy Merck announced interim results from a Phase II, multi-center, randomized, dose-ranging study (n=332) assessing the safety and antiviral activity of MK-5172, an investigational, once-daily, oral NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus, HCV, genotype 1 infection in combination therapy in treatment-naïve patients. These data will be presented this week at the American Association for the Study of Liver Diseases Annual Meeting, AASLD. In the initial cohort, termed the "Vanguard Cohort," (n=136), 96 percent of patients (25/26) who received a regimen containing 100 mg QD of MK-5172 with PR achieved sustained virologic response, SVR, 12, defined as having undetectable virus (HCV RNA) 12 weeks after treatment ended, compared to 54 percent of patients (13/24) in the control arm. “We are excited by these interim results evaluating MK-5172 in combination therapy,” said Eliav Barr, M.D., vice president, Infectious Diseases, Project Leadership and Management, Merck Research Laboratories. “Our commitment to chronic hepatitis C remains steadfast. We look forward to continuing our studies of MK-5172, including in interferon-free regimens." Currently planned studies evaluating interferon-free regimens with MK-5172 will be dosed at 100 mg QD. . News For MRK From The Last 14 Days Check below for free stories on MRK the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 09:39 EDT MRK Active equity option families trading Subscribe for More Information 07:45 EDT MRK FDA Peripheral & Central Nervous System Drugs Advisory Committee holds a meeting Subscribe for More Information May 21, 2013 18:56 EDT MRK On The Fly: After Hours Movers Subscribe for More Information 17:03 EDT MRK Merck announces $5B share repurchase Subscribe for More Information 17:01 EDT MRK Merck announces $5B accelerated share repurchase Subscribe for More Information 07:44 EDT MRK Sachs Associates to host a forum Subscribe for More Information May 20, 2013 17:49 EDT MRK Merck sleep drug effective, dosages questioned, WSJ reports Subscribe for More Information 07:32 EDT MRK Society for Information Display / IHS to host a conference Display Week 2013 is being held in Vancouver, British Columbia on May 19-24. May 16, 2013 08:55 EDT MRK BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information May 14, 2013 17:39 EDT MRK Moody's lowers Merck's guaranteed debt to A1 from Aa3; stable outlook Moody's Investors Service lowered the long-term ratings of Merck by one notch, including the guaranteed senior unsecured rating to A1 from Aa3 and the non-guaranteed senior unsecured rating to A2 from A1. This action concludes a review for downgrade initiated on May 1, 2013. At the same time, Moody's affirmed Merck's Prime-1 commercial paper rating. The rating outlook is stable. May 10, 2013 11:48 EDT MRK Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 06:53 EDT MRK GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says Subscribe for More Information May 9, 2013 07:22 EDT MRK Merck awarded significant portion of UNICEF HPV vaccine tender Subscribe for More Information May 8, 2013 08:32 EDT MRK Merck says FDA accepts biologics license application for allergy tablet Merck announced that the Biologics License Application for its investigational ragweed pollen sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration. The BLA for Merck’s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis. On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen sublingual allergy immunotherapy tablet. Merck expects the FDA’s review for both to be completed in the first half of 2014. Sign up for a free trial to see the rest of the stories you've been missing.